ResearcherWannan Medical CollegeNo recent work listed

Hongping Xia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6454-2333; OpenAlex author ID A5049252104. Sources: OpenAlex.

Their work

Papers: 5 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 13

Papers, trials and grants by year

2021: 2 papers · 2022: 3 papers

Papers 5

6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Caspase-dependent cell death in pancreatic… Co-author DOI 10.1016/j.phymed.2022.154164 ↗
KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41401-021-00688-3 ↗
PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer. Last author DOI 10.1159/000521588 ↗
S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Co-author DOI 10.1007/s10565-020-09574-w ↗
Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2020.10.039 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alaa Abdelatty · 3 shared papers, 2021–2022 · strength 0.41
Linhua Lan · 3 shared papers, 2021–2022 · strength 0.39
Xiao Mo · 3 shared papers, 2021–2022 · strength 0.38
Dan Fang · 2 shared papers, 2021–2022 · strength 0.28
- Paper PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer. DOI 10.1159/000521588 ↗
- Paper S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. DOI 10.1007/s10565-020-09574-w ↗
Nengfang Ma · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Fugen Shangguan · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Shijia Wu · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Huimin Huang · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Hailong Yang · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Guihua Jin · 1 shared paper, 2022 · strength 0.14
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164 ↗
Xin Guo · 1 shared paper, 2022 · strength 0.13
- Paper KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma. DOI 10.1038/s41401-021-00688-3 ↗
Hongjin Chen · 1 shared paper, 2021 · strength 0.13
- Paper Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progressio… DOI 10.1016/j.ygeno.2020.10.039 ↗
Xiaoming Wang · 1 shared paper, 2021 · strength 0.13
- Paper Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progressio… DOI 10.1016/j.ygeno.2020.10.039 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.